Abstract

Nanomedicine has emerged as a transformative approach in oncology, offering promising advances in cancer 
diagnostics, targeted therapy, and personalized treatment. Despite its immense potential, concerns regarding 
the toxicological profile, biosafety, and regulatory approval of nanomedical formulations remain significant 
barriers to clinical translation. This review provides a comprehensive analysis of the toxicological implications 
and regulatory considerations associated with nanomedicine use in oncology. It discusses the pharmacokinetics, 
biodistribution, immunogenicity, and potential cytotoxicity of various nanocarriers, including liposomes, 
dendrimers, metallic nanoparticles, and polymeric nanostructures. The review highlights the challenges in 
evaluating long-term safety due to the unique physicochemical properties of nanoparticles, such as size, shape, 
surface charge, and coating. Furthermore, we examine the current regulatory frameworks adopted by agencies 
like the FDA and EMA, focusing on preclinical evaluation, Good Manufacturing Practices (GMP), clinical trial 
design, and post-marketing surveillance. Case studies of approved nano-oncology drugs such as Doxil® and 
Abraxane® are presented to elucidate the pathway from bench to bedside. The article underscores the urgent 
need for standardized toxicity testing protocols, harmonized regulatory guidelines, and multidisciplinary 
collaboration to ensure the safe and effective integration of nanomedicine into routine oncologic care. As the 
field advances, addressing these toxicological and regulatory challenges will be crucial to harnessing the full 
therapeutic potential of nanotechnology in cancer treatment.